Hexagon Capital Partners LLC Has $280,000 Position in Danaher Co. (NYSE:DHR)

Hexagon Capital Partners LLC raised its holdings in Danaher Co. (NYSE:DHR) by 5.0% during the 4th quarter, Holdings Channel reports. The institutional investor owned 1,211 shares of the conglomerate’s stock after acquiring an additional 58 shares during the quarter. Hexagon Capital Partners LLC’s holdings in Danaher were worth $280,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in DHR. Brookstone Capital Management grew its position in shares of Danaher by 38.1% in the 3rd quarter. Brookstone Capital Management now owns 10,032 shares of the conglomerate’s stock valued at $2,489,000 after acquiring an additional 2,767 shares during the period. Accurate Wealth Management LLC grew its stake in Danaher by 32.7% in the 3rd quarter. Accurate Wealth Management LLC now owns 1,555 shares of the conglomerate’s stock valued at $386,000 after buying an additional 383 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its stake in Danaher by 3.7% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 47,915 shares of the conglomerate’s stock valued at $11,888,000 after buying an additional 1,705 shares during the last quarter. Robeco Institutional Asset Management B.V. grew its position in shares of Danaher by 14.7% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 78,520 shares of the conglomerate’s stock worth $19,481,000 after purchasing an additional 10,045 shares in the last quarter. Finally, Joel Isaacson & Co. LLC grew its position in shares of Danaher by 6.5% during the 3rd quarter. Joel Isaacson & Co. LLC now owns 1,714 shares of the conglomerate’s stock worth $425,000 after purchasing an additional 105 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Price Performance

NYSE:DHR traded down $1.45 on Wednesday, hitting $245.17. The company had a trading volume of 502,044 shares, compared to its average volume of 2,757,685. The stock has a market capitalization of $181.59 billion, a price-to-earnings ratio of 41.81, a PEG ratio of 3.80 and a beta of 0.83. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. The firm has a 50 day moving average of $248.78 and a two-hundred day moving average of $231.79. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $259.00.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.36 earnings per share. On average, research analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, April 26th. Stockholders of record on Thursday, March 28th were paid a dividend of $0.27 per share. The ex-dividend date was Wednesday, March 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. This is an increase from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of analyst reports. Royal Bank of Canada increased their target price on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Robert W. Baird increased their target price on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Citigroup upped their price target on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Raymond James upped their price target on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Finally, KeyCorp upped their price target on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Six equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $269.64.

Insider Activity

In other news, EVP Joakim Weidemanis sold 22,433 shares of the firm’s stock in a transaction on Thursday, April 25th. The shares were sold at an average price of $250.46, for a total transaction of $5,618,569.18. Following the completion of the transaction, the executive vice president now owns 90,412 shares of the company’s stock, valued at $22,644,589.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Joakim Weidemanis sold 22,433 shares of the stock in a transaction on Thursday, April 25th. The shares were sold at an average price of $250.46, for a total transaction of $5,618,569.18. Following the completion of the sale, the executive vice president now directly owns 90,412 shares in the company, valued at $22,644,589.52. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Brian W. Ellis sold 4,000 shares of the stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the sale, the senior vice president now owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 106,565 shares of company stock valued at $26,641,364. Insiders own 10.90% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.